We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Thermo Fisher (TMO) Beats on Q3 Earnings, Raises 2021 View
Read MoreHide Full Article
Thermo Fisher Scientific Inc.'s (TMO - Free Report) third-quarter 2021 adjusted earnings per share of $5.76 beat the Zacks Consensus Estimate by 23.3%. The figure improved 2.3% year over year. The adjusted number excludes certain non-recurring expenses, including asset amortization and restructuring costs.
GAAP earnings per share were $4.79, reflecting a 1% drop on a year-over-year basis.
The company’s robust organic growth in the base business contributed to a strong bottom-line performance.
Revenues in the quarter under review grossed $9.33 billion, up 9.5% year over year. The top line exceeded the Zacks Consensus Estimate by 12%.
Quarter in Detail
Organic revenues in the reported quarter grew 7% year over year. While acquisitions contributed 1% to the top line, favorable currency translation too increased revenues by 1%. Organic revenue growth from the base business was 10% in the reported quarter. COVID-19 response revenues (effects of COVID-19 response revenues from acquired businesses and foreign currency translation) declined 2% in the reported quarter.
Thermo Fisher operates under four business segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Thermo Fisher Scientific Inc. Price, Consensus and EPS Surprise
Revenues at the Life Sciences Solutions segment (39.9% of total revenues) improved 9% year over year to $3.72 billion, while Analytical Instruments Segment sales (15.8%) rose 11% to $1.48 billion.
Revenues at the Laboratory Products and Services segment (37.4%) rose 12% to $3.49 billion. The Specialty Diagnostics segment (14.6%) recorded a 4.9% year-over-year decline in revenues to $1.36 billion.
Gross margin of 51.4% in the third quarter contracted 88 basis points (bps) year over year on a 7.7% rise in the cost of revenues. In the quarter, selling, general and administrative expenses increased 32.5% to $1.73 billion. Research and development expenses were $351 million, up 18.6% year over year. Adjusted operating margin for the quarter came in at 29.1%, reflecting a contraction of 439 bps.
The company exited the third quarter with cash and cash equivalents of $12.03 billion compared with $7.02 billion at the end of the second quarter. Cumulative net cash provided by operating activities at the end of the third quarter was $6.89 billion compared with $4.95 billion a year ago.
The company raised its revenue guidance for 2021 to $37.1 billion, indicating 15% reported growth over 2020 (earlier guidance was $35.90 billion, implying 11% reported growth expectation). Full-year adjusted EPS guidance has been raised to $23.37, indicating 20% growth over 2020 (previous guidance was $22.07, representing 13% year over year growth). The current Zacks Consensus Estimate for adjusted earnings and revenues is pegged at $22.13 and $36.05 billion, respectively, below the company expectation.
Our Take
Thermo Fisher ended the third quarter of 2021 with better-than-expected numbers. The company delivered a strong quarterly performance, leveraging on a significant rebound in its base business.
We are encouraged by the strong year-over-year revenue growth across each of its reporting segments. The raised 2021 guidance too buoys optimism.
On the flip side, in the quarter, COVID-19 response revenues were $2.05 billion, a reduction from the year-ago period. Gross and operating margin contraction in the third quarter was discouraging too.
Zacks Rank and Other Key Picks
Thermo Fisher currently carries a Zacks Rank #2 (Buy).
Quest Diagnostics, carrying a Zacks Rank #2 (Buy), reported third-quarter 2021 adjusted EPS of $3.96, which beat the Zacks Consensus Estimate by 33.8%. Third-quarter revenues of $2.77 billion outpaced the consensus mark by 12.6%.
Abbott reported third-quarter 2021 adjusted EPS of $1.40, which surpassed the Zacks Consensus Estimate by 52.2%. Third-quarter revenues of $10.93 billion outpaced the Zacks Consensus Estimate by 15.3%. It currently carries a Zacks Rank #2.
HCA Healthcare, carrying a Zacks Rank #2, reported third-quarter 2021 adjusted EPS of $4.57, surpassing the Zacks Consensus Estimate by 11.5%. Revenues of $15.28 billion surpassed the Zacks Consensus Estimate by 4.7%.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Thermo Fisher (TMO) Beats on Q3 Earnings, Raises 2021 View
Thermo Fisher Scientific Inc.'s (TMO - Free Report) third-quarter 2021 adjusted earnings per share of $5.76 beat the Zacks Consensus Estimate by 23.3%. The figure improved 2.3% year over year. The adjusted number excludes certain non-recurring expenses, including asset amortization and restructuring costs.
GAAP earnings per share were $4.79, reflecting a 1% drop on a year-over-year basis.
The company’s robust organic growth in the base business contributed to a strong bottom-line performance.
Revenues in the quarter under review grossed $9.33 billion, up 9.5% year over year. The top line exceeded the Zacks Consensus Estimate by 12%.
Quarter in Detail
Organic revenues in the reported quarter grew 7% year over year. While acquisitions contributed 1% to the top line, favorable currency translation too increased revenues by 1%. Organic revenue growth from the base business was 10% in the reported quarter. COVID-19 response revenues (effects of COVID-19 response revenues from acquired businesses and foreign currency translation) declined 2% in the reported quarter.
Thermo Fisher operates under four business segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Thermo Fisher Scientific Inc. Price, Consensus and EPS Surprise
Thermo Fisher Scientific Inc. price-consensus-eps-surprise-chart | Thermo Fisher Scientific Inc. Quote
Revenues at the Life Sciences Solutions segment (39.9% of total revenues) improved 9% year over year to $3.72 billion, while Analytical Instruments Segment sales (15.8%) rose 11% to $1.48 billion.
Revenues at the Laboratory Products and Services segment (37.4%) rose 12% to $3.49 billion. The Specialty Diagnostics segment (14.6%) recorded a 4.9% year-over-year decline in revenues to $1.36 billion.
Gross margin of 51.4% in the third quarter contracted 88 basis points (bps) year over year on a 7.7% rise in the cost of revenues. In the quarter, selling, general and administrative expenses increased 32.5% to $1.73 billion. Research and development expenses were $351 million, up 18.6% year over year. Adjusted operating margin for the quarter came in at 29.1%, reflecting a contraction of 439 bps.
The company exited the third quarter with cash and cash equivalents of $12.03 billion compared with $7.02 billion at the end of the second quarter. Cumulative net cash provided by operating activities at the end of the third quarter was $6.89 billion compared with $4.95 billion a year ago.
Meanwhile, Thermo Fisher has been consistently paying dividends, with the 5-year annualized dividend growth being 13.55%.
Guidance
The company raised its revenue guidance for 2021 to $37.1 billion, indicating 15% reported growth over 2020 (earlier guidance was $35.90 billion, implying 11% reported growth expectation). Full-year adjusted EPS guidance has been raised to $23.37, indicating 20% growth over 2020 (previous guidance was $22.07, representing 13% year over year growth). The current Zacks Consensus Estimate for adjusted earnings and revenues is pegged at $22.13 and $36.05 billion, respectively, below the company expectation.
Our Take
Thermo Fisher ended the third quarter of 2021 with better-than-expected numbers. The company delivered a strong quarterly performance, leveraging on a significant rebound in its base business.
We are encouraged by the strong year-over-year revenue growth across each of its reporting segments. The raised 2021 guidance too buoys optimism.
On the flip side, in the quarter, COVID-19 response revenues were $2.05 billion, a reduction from the year-ago period. Gross and operating margin contraction in the third quarter was discouraging too.
Zacks Rank and Other Key Picks
Thermo Fisher currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks in the broader medical space that have announced quarterly results are Quest Diagnostics Incorporated (DGX - Free Report) , Abbott Laboratories (ABT - Free Report) , and HCA Healthcare, Inc. (HCA - Free Report) . You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
Quest Diagnostics, carrying a Zacks Rank #2 (Buy), reported third-quarter 2021 adjusted EPS of $3.96, which beat the Zacks Consensus Estimate by 33.8%. Third-quarter revenues of $2.77 billion outpaced the consensus mark by 12.6%.
Abbott reported third-quarter 2021 adjusted EPS of $1.40, which surpassed the Zacks Consensus Estimate by 52.2%. Third-quarter revenues of $10.93 billion outpaced the Zacks Consensus Estimate by 15.3%. It currently carries a Zacks Rank #2.
HCA Healthcare, carrying a Zacks Rank #2, reported third-quarter 2021 adjusted EPS of $4.57, surpassing the Zacks Consensus Estimate by 11.5%. Revenues of $15.28 billion surpassed the Zacks Consensus Estimate by 4.7%.